When will Fam-trastuzumab deruxtecan-nxki be included in medical insurance?

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) The original drug was approved by the State Food and Drug Administration in 2023 and will be launched in the country. Therefore, it has not yet entered the scope of medical insurance. This drug is a strictly controlled drug. The domestic price and the specific time to enter the national medical insurance are not yet clear, and the purchase method is also difficult. For details, please consult the local medical insurance bureau and other places. The Hong Kong version of Trastuzumab Specifications may cost more than RMB 10,000 per box for 100 mg, and the Hong Kong original version of Trastuzumab Original Specifications may cost around RMB 15 for 100 mg per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same.